logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Figure INF-6. Estimated HCV antibody prevalence among injecting drug users – studies with national and subnational coverage [see all figures in this series...]

Part (ii) Young injecting drug users (aged under 25), 2004 - 2005


Black square = samples with national coverage; blue triangle = samples with subnational (including local or regional) coverage.

Differences between countries should be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary.

Countries are presented by order of increasing prevalence, based on the average of national data or, if not available, of subnational data.

* Czech Republic: data is from 2003


SB2006: Figure INF-6 part (ii)

For primary sources, study details and data before 2004, see Table INF-12 and Table INF-0.

See also 'General notes for interpreting data' on the Explanatory notes and help page.


Reitox national focal points

(see the help page for information on formats etc.)

Page last updated: Thursday, 22 November 2007